AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 SEP 2 - (NewsRx.com & NewsRx.net) -- Bcl-2 antisense oligodeoxynucleotide chemosensitizes breast carcinoma cells.
According to recent research published in the journal Breast, "this study was designed to observe whether the rates of apoptosis induced in the breast cancer cell line MCF-7 by 5-fluorouracil (5-FU) could be enhanced by transfecting bcl-2 antisense oligonucleotide (ASODN). In our experiment, bcl-2 ASODNs and control ODNs, including untreated control, sense ODN, and scrambled ODN, were transfected into MCF-7 cells."
"Changes in expression of the bcl-2 gene were examined by Western blot; cell growths were detected by MTT assay, and apoptosis rates were detected by flow cytometry (FCM). Expression of bcl-2 protein after transfection of bcl-2 ASODN was significantly lower than control ODNs. Moreover, incubation of MCF-7 with bcl-2 ASODN prior to 5-FU treatment caused remarkable loss of viable cells compared with all other control ODNs (p
"FCM showed the apoptosis rates for ASODN, untreated control, sense ODN and scrambled ODN (29.8[+ or -]7.4)%, (8.0[+ or -]2.3)%, (15.0[+ or -]5.1)% and (16.5[+ or -]7.1)%, respectively. Compared with control ODNs, ...
Source: HighBeam Research, Bcl-2 antisense oligodeoxynucleotide chemosensitizes breast carcinoma...